Anthem Biosciences Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 3,302

Employees

  • Stock Symbol
  • ANTHEM

Stock Symbol

  • Share Price
  • $10.02
  • (As of Thursday Closing)

Anthem Biosciences General Information

Description

Anthem Biosciences Ltd is mainly engaged in discovering, developing, manufacturing, and commercializing biopharmaceutical products that address unmet needs and provide biological solutions to improve industrial performance in all areas. The company offers its CRDMO services to biotech, pharmaceutical, and other companies for the development of large and small drug molecules, and also runs a products business offering specialty ingredients like fermentation products, peptides, lipids, probiotics, APIs, biosimilars, etc. Its reportable segments are: Contract Research Development and Manufacturing Services (CRDMO), which derives maximum revenue, and Specialty Ingredients. Geographically, the company generates maximum revenue from Europe, followed by North America, India, and other regions.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Number 49, F1&F2, Canara Bank Road, Hosur Rd, Electronics City Phase 1
  • Bommasandra Industrial Area
  • Bengaluru, Karnataka 560099
  • India
+91 080667
Primary Industry
BPO/Outsource Services
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NSE
Corporate Office
  • Number 49, F1&F2, Canara Bank Road, Hosur Rd, Electronics City Phase 1
  • Bommasandra Industrial Area
  • Bengaluru, Karnataka 560099
  • India
+91 080667

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anthem Biosciences Stock Performance

As of 19-Nov-2026, Anthem Biosciences’s stock price is $10.02. Its current market cap is $5.65B with 564M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.02 $9.78 $6.32 - $10.53 $5.65B 564M 659K $0.12

Anthem Biosciences Financials Summary

As of 30-Sep-2026, Anthem Biosciences has a trailing 12-month revenue of $221M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 4,945,273 3,784,710
Revenue 220,704 240,408 218,143 171,451
EBITDA 106,841 100,220 81,785 63,725
Net Income 66,219 66,972 53,367 44,369
Total Assets 383,793 363,455 328,221 287,566
Total Debt 4,286 5,715 13,247 28,601
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Anthem Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Anthem Biosciences‘s full profile, request access.

Request a free trial

Anthem Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Anthem Biosciences Ltd is mainly engaged in discovering, developing, manufacturing, and commercializing biopharmaceutica
BPO/Outsource Services
Bengaluru, India
3,302 As of 2026

Hyderabad, India
 

Irvine, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Anthem Biosciences Competitors (22)

One of Anthem Biosciences’s 22 competitors is Sai Life Sciences, a Formerly VC-backed company based in Hyderabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sai Life Sciences Formerly VC-backed Hyderabad, India
BioDuro-Sundia Private Equity-Backed Irvine, CA
OneSource Specialty Pharma Formerly VC-backed Bengaluru, India
Cipla Corporation Mumbai, India
Evotec Formerly PE-Backed Hamburg, Germany
You’re viewing 5 of 22 competitors. Get the full list »

Anthem Biosciences Patents

Anthem Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023105497-A1 Synthesis of glp-1 analogues Inactive 10-Dec-2021
AU-2022297739-A1 A method for preparation of glycolipid carboxylic acids Pending 25-Jun-2021
EP-4358969-A2 A method for preparation of glycolipid carboxylic acids Pending 25-Jun-2021
EP-4358969-A4 A method for preparation of glycolipid carboxylic acids Pending 25-Jun-2021
US-20240318217-A1 A method for preparation of glycolipid carboxylic acids Active 25-Jun-2021 C12P19/26
To view Anthem Biosciences’s complete patent history, request access »

Anthem Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Anthem Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Anthem Biosciences‘s full profile, request access.

Request a free trial

Anthem Biosciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

31.18 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Anthem Biosciences’s complete esg history, request access »

Anthem Biosciences FAQs

  • When was Anthem Biosciences founded?

    Anthem Biosciences was founded in 2006.

  • Where is Anthem Biosciences headquartered?

    Anthem Biosciences is headquartered in Bengaluru, India.

  • What is the size of Anthem Biosciences?

    Anthem Biosciences has 3,302 total employees.

  • What industry is Anthem Biosciences in?

    Anthem Biosciences’s primary industry is BPO/Outsource Services.

  • Is Anthem Biosciences a private or public company?

    Anthem Biosciences is a Public company.

  • What is Anthem Biosciences’s stock symbol?

    The ticker symbol for Anthem Biosciences is ANTHEM.

  • What is the current stock price of Anthem Biosciences?

    As of 19-Nov-2026 the stock price of Anthem Biosciences is $10.02.

  • What is the current market cap of Anthem Biosciences?

    The current market capitalization of Anthem Biosciences is $5.65B.

  • What is Anthem Biosciences’s current revenue?

    The trailing twelve month revenue for Anthem Biosciences is $221M.

  • Who are Anthem Biosciences’s competitors?

    Sai Life Sciences, BioDuro-Sundia, OneSource Specialty Pharma, Cipla, and Evotec are some of the 22 competitors of Anthem Biosciences.

  • What is Anthem Biosciences’s annual earnings per share (EPS)?

    Anthem Biosciences’s EPS for 12 months was $0.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process